MedTrace Logo

Oxaliplatin and Capecitabine Versus Follow-up After Resection of Colorectal Liver Metastases

NCT00156975 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 384

Last updated 2009-12-25

No results posted yet for this study

Summary

Primary endpoint of the study is to prove the superiority of an adjuvant therapy with oxaliplatin/ capecitabine until the first occurrence of appearance of a tumour. Occurrences in the meaning of this study are the appearance of a relapse of the tumour, of metastases, of a second tumour or death of any reason.

Conditions

  • Colorectal Neoplasms
  • Liver Metastases

Interventions

DRUG

Capecitabine

DRUG

Oxaliplatin

Sponsors & Collaborators

  • Arbeitsgruppe Lebermetastasen und Tumoren

    lead OTHER

Principal Investigators

  • Wolf O. Bechstein, Prof. Dr. · Arbeitsgruppe Lebermetastasen und Tumoren

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-11-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00156975 on ClinicalTrials.gov